Kimmtrak Revenue Surge

Kimmtrak generated $106.7 million in first‑quarter 2026 revenue, a 14 % year‑over‑year increase, and totaled $400 million in 2025 sales, up 29 % from the previous year. The drug is approved in 39 countries, launched in more than 30, and its 5‑year phase III data showed a 16 % overall‑survival rate versus 8 % for control, reinforcing its first‑line positioning in metastatic uveal melanoma. Immunocore plans a phase III study of Kimmtrak as monotherapy and in combination with checkpoint inhibitors in advanced cutaneous melanoma after prior anti‑PD‑(L)1 treatment; positive results could extend the drug into a larger patient set.